CN108567737A - Liquid composition and its use device - Google Patents
Liquid composition and its use device Download PDFInfo
- Publication number
- CN108567737A CN108567737A CN201710142752.5A CN201710142752A CN108567737A CN 108567737 A CN108567737 A CN 108567737A CN 201710142752 A CN201710142752 A CN 201710142752A CN 108567737 A CN108567737 A CN 108567737A
- Authority
- CN
- China
- Prior art keywords
- liquid composition
- acid
- composition
- eye
- atomized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Medicinal Preparation (AREA)
Abstract
This application involves a kind of liquid composition and its use device, the application further relates to application of the described device in alleviating or eliminating ophthalmic uncomfortable.
Description
Technical field
This application involves a kind of liquid composition and its use device, the application further relates to described device and is alleviating or eliminating
Application in ophthalmic uncomfortable.
Background technology
With the development of science and technology the people that stare at computer work, object for appreciation mobile phone and trip of driving daily now is more and more.
However, long-time sees computer, object for appreciation mobile phone and trip of driving frequently results in eye fatigue, there is the symptom of ophthalmic uncomfortable, such as
Eyes are dry and astringent, are easy tired, eye itches, has sticky foreign body sensation, pain burning heat sensation, secretion, is fear of wind, photophobia, sensitive to environmental stimuli；
Sometimes eyes are too dry, basic oligodacrya, stimulate reflectivity lacrimal secretion instead, and cause usually to shed tears；More severe case eyes
Meeting redness, hyperemia, keratinization, corneal epithelial wound, and there is filiform to stick, with the passing of time this damage can then cause angle conjunctiva sick
Become, and can affect vision, directly affects the work and life of people.
Eye skin is very thin, and thickness only has 1/5th of facial skin, highly brittle hyposensitiveness sense.And eye skin will not
Grease is secreted, drying is easy.Therefore, moisturizing is releived eye skin, alleviation for ophthalmic uncomfortable or to eliminate be also extremely important
's.
Now, dry eye morbidity rate is higher, is primarily due to the very big universal caused of plane electronics product.According to dry eye condition
Pathogenic factor, US National institute of ophthalmology nineteen ninety-five be classified as tear type under production and evaporated strong type (see
Lemp MA.Report of the National Eye Institute/Industry workshop on Clinical
Trials in Dry Eyes.CLAO J.1995；21:221-232).
Meibomian gland dysfunction is to cause the most common reason for evaporating strong type xerophthalmia, and Meibomian gland dyslipidemias is eyelid
The most important performance of plate gland dysfunction.Eyelid fat ingredient includes mainly phosphatide, cholesteryl ester, neutral fat, free fatty etc..
The change of eyelid fat ingredient makes tear evaporation accelerate, tear film osmotic pressure increases and shortens with breakup time of tear film, so as to cause margo palpebrae
Bacterial growth evaporated the damage such as strong type dry eyes and ocular inflammation (see Joffre C, Souchier M, Gregoire S, et
al.Differences in meibomian fatty acid composition in patients with meibomian
gland dysfunction and aqueous-deficient dry eye.Br J Ophthalmol,2008,92(1):
116–119)。
In order to improve the symptom of ophthalmic uncomfortable, common method is dropwise addition eye drops at present, but not due to eye drops application
Convenient, the compliance of some patientss is very low.In addition, the administration of secondary high local concentrations more than a day, directly acts on eyeball, it can be to eye
Ball generates stimulation and side effect, such as mucous membrane pain, eyelid skin flush, chemosis symptom occurs.
Therefore, there is still a need for new products and device to eliminate or alleviate ophthalmic uncomfortable.
Invention content
Therefore, the application relates in one aspect to a kind of liquid composition, it includes in phosphatide, water and following components one kind or
It is a variety of：Moisturizer, bacteriostatic agent, aromatic, antioxidant and pH adjusting agent.
On the other hand, the application further relates to a kind of spraying device, and it includes the compositions of the application and mist to generate unit,
On startup, which generates the mist that unit generates the composition.
Description of the drawings
Fig. 1 is the structural schematic diagram of an exemplary spray device used herein.
Fig. 2 is comparison diagram before the embodiment of the present application composition 1,2 and the centrifugation of commercially available product 1,2.
Fig. 3 is comparison diagram after the embodiment of the present application composition 1,2 and the centrifugation of commercially available product 1,2.
Fig. 4 is the structural schematic diagram of another exemplary spray device used herein.
Specific implementation mode
Clinical research has been found that phospholipid fraction is substantially reduced in the tears of patients with dry eye, and faces with various xerophthalmia
Bed parameter is related, such as eye surface diseases index and breakup time of tear film.It is filled by liquid composition provided by the present application and spraying
The phospholipid fraction of missing can effectively be supplemented by setting, and alleviate dry eye symptoms.
In the liquid composition of the application, the phosphatide is selected from natural phospholipid (such as soybean lecithin, yolk phospholipid), two palm fibres
It is palmitic acid phosphatidyl choline, phosphatidyl-ethanolamine, phosphatidyl glycerol, phosphatidyl choline, phosphatidylserine, phosphatidylinositols, sweet
Oily phosphatidic acid, cuorin, sphingomyelins and glycosyl sphingolipid.Constituent content used can change in wide range.The liquid group
Close a concentration of 0.01-0.5wt%, 0.01%-0.05wt%, 0.05%-0.1wt%, 0.1%- that object may include phosphatide
0.2wt%, 0.2%-0.4wt%, 0.4%-0.5wt% etc..
In this application, the moisturizer is selected from propylene glycol, glycerine, butanediol, sorbierite, polyethylene glycol, urea, allantois
Element, hyaluronic acid, lactic acid and sodium lactate.The content of the moisturizer can change in wide range, a concentration of 0.05%-
5wt%, 0.05%-0.5wt%, 0.5%-1.0wt%, 1.0%-2wt%, 2.0%-3wt%, 3.0%-4.0wt%,
4.0%-5wt% etc..
To improve the storage time of liquid composition, avoids growing bacterium, may be used also in liquid composition provided by the present application
Including other bacteriostatic agent, such as, but not limited to parabens and its salt, benzoic acid and its salt, benzyl alcohol, benzyl carbinol, benzene second
Acid, lauric monoglyceride, anesin, sorbic acid and its salt, calcium propionate, sodium propionate, dehydroactic acid and its salt, diacetic acid
Sodium, benzalkonium chloride, benzalkonium bromide, cetrimonium bromide, chlorhexidine acetate, nisin, receives that he is mould at lauric monoglyceride fat
Element, Charantin, thimerosal and mercuric nitrate.
The additive amount of above-mentioned bacteriostatic agent can change in wide range.It is preferred that these antibacterial agent contents are 0.01-
2.0wt%, 0.01-0.5wt%, 0.5-1.0wt%, 1.0-1.5wt%, 1.5-2.0wt%.
In order to improve the compliance of liquid composition, other fragrance is may also include in liquid composition provided by the present application
Agent, such as, but not limited to borneol, lemon oil, patchouli oil, cinnamon oil, red date tincture, vanillic aldehyde, peppermint oil dementholized, French geranium oil,
Eucalyptus oil, spearmint oil, eugenol, citral, concrete of jasmine, Hang Zhou chrysanthemum flower extract, osmanthus concrete, benzyl alcohol, benzyl carbinol, pine tar
Alcohol, methyl cyclopentenyl ketone, jasminal, butyric acid, caproic acid, isoamyl acetate, benzyl acetate, bergamio, propionic acid
Ethyl ester, ethyl butyrate, isoamyl butyrate, benzyl butyrate, iso-amyl iso-valeriate, ethyl hexanoate, cognac oil, ethyl lactate, oneself
Allyl propionate,Nonalactone, ethylmaltol, allyl cyclohexyl propionate, maltol,Undecalactone (peach aldehyde), raspberry
Ketone (4-(4-hydroxyphenyl)-2-butanone), benzyl propionate, butyl butyrate, ethyl isovalerate, Ethyl formate, Ergol, methylpyrazine, 2,3- bis-
Methylpyrazine, trimethylpyrazine, 2- acetyl group pyrazine, 4- methyl -5- (beta-hydroxyethyl) thiazole, 2- acetylthiazoles, 2,3,5,
6- Tetramethylpyrazines, hexadecanoyl (strawberry aldehyde, strawberry aldehyde), Ethyl vanillin, laurine and it is known in the art rectify
It is one or more in taste agent, essence.
The additive amount of above-mentioned aromatic can change in wide range, these fragrance levels are 0.01-5.0wt%,
0.01-0.5wt%, 0.5-1.0wt%, 1.0-1.5wt%, 1.5-2.0wt%, 2.0-3.0wt%, 3.0-4.0wt%, 4.0-
5.0wt% etc..
Can also include antioxidant in liquid composition provided by the present application.The antioxidant is selected from but not limited to tertiary butyl
Hydroxyanisole, dibutyl hydroxy toluene, tert-butyl hydroquinone, propylgallate, ascorbyl palmitate, thio two
Propionic acid dilaurate, 4- hexyl resorcins, tocopherol (vitamin E), L-AA, D-araboascorbic acid sodium, tea are more
Phenol, Rosmarinus officinalis extract, Ginger P.E, glycitols carbohydrate, amino acid and dipeptides amino acid.
The additive amount of above-mentioned antioxidant can change in wide range.Such antioxidant content is 0.001-5.0wt%,
0.001-0.005wt%, 0.005-0.05wt%, 0.05-0.1wt%, 0.1-0.5wt%, 0.5-1.0wt%, 1.0-
2.0wt%, 2.0-3.0wt%, 3.0-4.0wt%, 4.0-5.0wt% etc..
In order to increase the compliance that eye uses, the pH adjusting agent is selected from citric acid, sulfuric acid, phosphoric acid, hydrochloric acid, hydroxide
The range of sodium, potassium hydroxide and calcium hydroxide, pH can change in wide range.The pH value of the application liquid composition is adjustable
Section is 5.0-7.4,5.0-5.5,5.5-6.0,6.0-6.5,6.5-7.0 and 7.0-7.4 etc..
To improve the resultant effect of the application liquid composition, drug can also be contained in the liquid composition in the application
Ingredient, the drug ingedient include preventing or treating eye disease or the various drugs of illness.
Present invention also provides a kind of spraying devices comprising the liquid composition and mist of the application generates unit, institute
It states mist and generates the mist that unit generates the composition on startup.
As shown in Figure 1, it includes the container for storing liquid, the liquid atomization shape for that will store that the mist, which generates unit,
At the oscillation nebulising element of spraying, it is equipped with perforation in the container to the recirculation hole of the oscillation nebulising element, stores liquid
It flow to oscillation nebulising element through the recirculation hole and spraying can be formed, it further includes shell which, which generates unit, described outer
It is configured with the nozzle sprayed conducive to spraying on shell, is equipped on the housing slidably and covers in the push button of the nozzle,
Shell on the inside of the push button is equipped with microswitch, and battery management circuit and high-frequency oscillating circuits are equipped in the shell,
The microswitch, oscillation nebulising element are electrically connected with the high-frequency oscillating circuits respectively, when the promotion push button exposes institute
When stating nozzle, the push button acts on the microswitch and the high-frequency oscillating circuits is made to be connected to, and causes to vibrate nebulising element
High-frequency vibration is sprayed so that can be sprayed from the nozzle；It is described to push away when pushing the push button and cover in the nozzle
Button acts on the microswitch and the high-frequency oscillating circuits is made to disconnect, and oscillation nebulising element stops vibration, wherein the appearance
Liquid in device is the liquid composition of the application.
Fig. 4 is the variant of spraying device shown in Fig. 1.As shown in figure 4, other than said elements, which also wraps
Containing eyeshade.
According to the application, it is not particularly limited in the spraying device for storing the volume of a container of liquid.Generally
1-50mL, preferably 5-30mL, more preferable 10-25mL.The median particle diameter that stored liquid generates drop after atomization is usually
50-1000nm, preferably 50-500nm, more preferable 100-500nm, atomization rates are generally 0.5-2.5mL/min, preferably 1-2mL/
Min, more preferable 1-1.5mL/min.The frequency that oscillation nebulising element generates vibration is not particularly limited, as long as produced atomized liquid
The grain size and atomization rates of drop are in above range.
In the eye irritation experiment of single administration and the eye irritation experiment of multiple applications, made using known eye drops
For control, with individual the application liquid composition, the application liquid composition for being encased in eye drops bottle, it is adsorbed onto eye
The application liquid composition in patch and the application liquid composition being encased in the application spraying device are compared, and are tied
Fruit shows that the eye irritation of the liquid composition of the application is substantially less than known eye drops, wherein using spraying device
When, the effect of liquid composition is best.
The application liquid composition, therefore can be repeatedly frequent to the irritation very little of eyes or almost without irritation
It uses, and therefore provides great convenience for the patient of ophthalmic uncomfortable.Especially for the people for trip of driving, can greatly delay
The eye fatigue for solving driver, to reduce traffic accident.
In addition, compared with conventionally used eye drops, the liquid composition of the application can also significantly improve stability.
The present invention is further detailed below by way of specific embodiment, these embodiments are not limited to this
Invention.
One, the preparation of embodiment sample
1, test material
1.1 reagents that use in test are as follows：
Soybean lecithin, vitamin e acetate, glycerine, Phenoxyethanol, urea, menthol and purified water, commercially available product 1 are commercially available
Product 2.
1.2 instrument and equipments that use in test are as follows：
The mechanical, electrical sub- balance of high-speed homogenization, pH meter, high pressure homogenizer and small-sized high speed centrifugal machine.
Recipe quantity is as follows：
2. experimental method and step
The preparation process of 2.1 liquid compositions
1) urea weighs dissolving
Recipe quantity urea is weighed in 250mL flasks, adding purified water 250g, stirring to be allowed to be completely dissolved, obtains feed liquid A.
2) glycerine, Phenoxyethanol and menthol for weighing recipe quantity are added in container appropriate, and stirring is allowed to completely molten
Solution obtains feed liquid B.
3) feed liquid B is added in feed liquid A, it is preliminary to stir.Weigh again recipe quantity soybean lecithin and vitamin e acetate or
Retinol Palmitate is added in the above solution.
4) high-speed homogenization is handled
The homogenate machine rotor for having cleaned, having sterilized is inserted into the container for containing feed liquid and is homogenized.
5) after the completion of being homogenized, pH monitorings.
6) high-pressure homogeneous processing
Using cleaned, the high pressure homogenizing that sterilizes processing.
7) filtration treatment
Using 0.22 micron of filtering with microporous membrane of sterilization treatment.
8) pH measurement and study on the stability
A) pH is measured, and pH value is measured using pH meter
| Sample ID | Embodiment 1 | Embodiment 2 | Commercially available product 1 | Commercially available product 2 |
| pH | 5.94 | 5.59 | 5.39 | 7.08 |
B) accelerated test (centrifugal stability)
Assay method：Prepare 4 2.5mL centrifuge tubes, is separately added into feed liquid each 1mL, 1800rcf centrifugation after the completion of extrusion
10h, observes whether it layering, flocculation occurs or merge phenomenon (experimental result is shown in Fig. 2 and Fig. 3).
Two, rabbit dry eye model is tested
1. the foundation of rabbit dry eye model
With reference to method [Gilbard JP, Scott R, Rossi SR, the et al.Tear film and of Gilbard
ocular surface changes after closure of the meibomian gland orifices in the
rabbit.Ophthalmology,1989,96(8):1180-1186] rabbit dry eye model is established, the liquid for evaluating the present invention
The effect of composition and device in terms of improving dry eyes.
Healthy new zealand white rabbit 8, half male and half female, weight 2.2-2.5kg.Every random selection makes dry eyes mould at a glance
Type, step are summarized as follows:Under surgical operation microscope, upper all Meibomian glands of lower eyelid at a glance are burnt using disposable cauter one by one and are opened
Mouthful, each opening burns time about 1s, postoperative that infection conjunctival sac is prevented to apply neomycin eye ointment.Postoperative 2nd day, check that Meibomian gland is opened
Mouth situation is given supplement and is burnt if any opening.Second eye is as a contrast.Occurs dry eyes table that is apparent and stablizing after postoperative 6th week
It is existing, to establish rabbit dry eyes animal model.
2. experimental method
The dry eyes of every rabbit use homemade spraying device, using the sample of embodiment 1, carry out spraying treatment, 10 seconds/
It is secondary, 4 times/d.Second eye is not treated then.
4. evaluation index
The front and back 7d of spraying, detects more every rabbit dry eyes and Second eye breakup time of tear film (BUT), basic lacrimal secretion are real
It tests (SIt).
5. interpretation of result
Every rabbit dry eyes and control eye BUT, SIt compare
After treating 7d, this two indexs of dry eyes group BUT, SIt take a favorable turn, and compared with Second eye group, there was no significant difference.
Claims (26)
1. a kind of liquid composition, the composition includes one or more in phosphatide, water and following components：Moisturizer, suppression
Microbial inoculum, aromatic, antioxidant and pH adjusting agent.
2. composition according to claim 1, wherein the phosphatide is selected from natural phospholipid (such as soybean lecithin, yolk phosphorus
Fat), dipalmitoylphosphatidylcholine, phosphatidyl-ethanolamine, phosphatidyl glycerol, phosphatidyl choline, phosphatidylserine, phosphatidyl
Inositol, glycerophosphatide acid, cuorin, sphingomyelins and glycosyl sphingolipid.
3. composition according to claim 1, wherein if it exists, the moisturizer is selected from propylene glycol, glycerine, fourth
Glycol, sorbierite, polyethylene glycol, urea, allantoin, hyaluronic acid, lactic acid and sodium lactate.
4. composition according to claim 1, wherein if it exists, the bacteriostatic agent be selected from parabens and its
Salt, benzoic acid and its salt, benzyl alcohol, benzyl carbinol, phenylacetic acid, Phenoxyethanol, lauric monoglyceride, anesin, sorb
Acid and its salt, calcium propionate, sodium propionate, dehydroactic acid and its salt, sodium Diacetate, lauric monoglyceride fat, benzalkonium chloride, benzene bundle bromine
Ammonium, cetrimonium bromide, chlorhexidine acetate, nisin, natamycin, Charantin, thimerosal and mercuric nitrate.
5. composition according to claim 1, wherein if it exists, the aromatic is selected from menthol, borneol, lemon
Lemon oil, patchouli oil, cinnamon oil, red date tincture, vanillic aldehyde, peppermint oil dementholized, French geranium oil, eucalyptus oil, spearmint oil, cloves
Phenol, citral, concrete of jasmine, Hang Zhou chrysanthemum flower extract, osmanthus concrete, benzyl alcohol, benzyl carbinol, terpinol, methyl cyclopentenyl ketone, α-
Amyl cinnamic aldehyde, butyric acid, caproic acid, isoamyl acetate, benzyl acetate, bergamio, ethyl propionate, ethyl butyrate, butyric acid are different
Pentyl ester, benzyl butyrate, iso-amyl iso-valeriate, ethyl hexanoate, cognac oil, ethyl lactate, allyl hexanoate, Y- nonalactones, second
Base maltol, allyl cyclohexyl propionate, maltol, Y- undecalactones (peach aldehyde), raspberry ketone (4-(4-hydroxyphenyl)-2-butanone), propionic acid benzyl
Ester, butyl butyrate, ethyl isovalerate, Ethyl formate, Ergol, methylpyrazine, 2,3- dimethyl pyrazines, trimethyl pyrrole
Piperazine, 2- acetyl group pyrazine, 4- methyl -5- (beta-hydroxyethyl) thiazole, 2- acetylthiazoles, 2,3,5,6- Tetramethylpyrazines, 16
Aldehyde (strawberry aldehyde, strawberry aldehyde), Ethyl vanillin and laurine.
6. composition according to claim 1, wherein if it exists, the antioxidant is selected from tert-butyl hydroxy fennel
Ether, dibutyl hydroxy toluene, tert-butyl hydroquinone, propylgallate, ascorbyl palmitate, thiodipropionic acid dilauryl
Cinnamic acid ester, 4- hexyl resorcins, tocopherol (vitamin E), L-AA, D-araboascorbic acid sodium, vitamin A palmitic acid
Ester, tea polyphenols, Rosmarinus officinalis extract, Ginger P.E, glycitols carbohydrate, amino acid and dipeptides amino acid.
7. composition according to claim 1, wherein if it exists, the pH adjusting agent be selected from citric acid, sulfuric acid,
Phosphoric acid, hydrochloric acid, sodium hydroxide, potassium hydroxide and calcium hydroxide.
8. according to the composition described in any one of claim 1-7, wherein a concentration of about 0.01wt% of the phosphatide is to about
0.5wt%.
9. according to the composition described in any one of claim 1-8, wherein if it exists, the content of the moisturizer is
The content of 0.05wt% to about 5wt%, the bacteriostatic agent are 0.01wt% to about 2.0wt%, and the content of the aromatic is
0.01wt% to about 5.0wt%, the content of the antioxidant are 0.01wt% to about 5.0wt%, appropriate pH adjusting agent, and condition is
The pH value of the liquid composition can be adjusted to 5.0-7.4 by it.
10. a kind of spraying device, it includes according to any one of claim 1-9 composition and mist generate unit,
On startup, which generates the mist that unit generates the composition.
11. a kind of spraying device for liquid composition to be delivered to eyes of patients in the form of being atomized hydrojet, the spraying
Device includes：
For delivery to the liquid composition of eyes of patients in need；
Container for storing the liquid composition；
Ultrasonic oscillating system, the liquid composition for being atomized by the ultrasonic oscillating system on startup；
Nozzle, the nozzle is for making the liquid composition of atomization leave the spraying device；With
Actuator, the actuator are used to control the startup of the ultrasonic oscillating system.
12. the spraying device according to claim 10 or 11, wherein the liquid composition is according in claim 1-9
Any one of them composition.
13. according to the spraying device described in claim 10-12, wherein the atomization hydrojet of the liquid composition includes intermediate value grain
Diameter is drops of the about 50nm to about 1000nm.
14. according to the spraying device described in any one of claim 10-13, the spraying device can be with about 0.5mL/min
Rate to about 2.5mL/min is atomized.
15. according to the spraying device described in any one of claim 10-14, wherein the container can accommodate about 1mL to about
The liquid composition of 50mL.
16. a kind of method for liquid composition to be delivered to eyes of patients in the form of being atomized hydrojet, the method includes：
Liquid composition is atomized using ultrasonic oscillating system, forms the atomization hydrojet of the liquid composition, the atomization hydrojet
It is drops of the about 50nm to about 1000nm including median particle diameter；It is in need with the atomization hydrojet of liquid composition to be delivered to
Patient eye.
17. according to the method for claim 16, wherein the liquid composition is according to any one of claim 1-9 institute
The composition stated.
18. method according to claim 16 or 17, wherein the median particle diameter of the drop is about 100-500nm.
19. according to the method described in any one of claim 16-18, wherein with about 0.5mL/min to the speed of about 2.5mL/min
Rate is atomized the liquid composition.
20. according to the method described in any one of claim 16-19, wherein the patient suffers from illness selected from the following：Eye
Eyeball is dry and astringent, is easy tired, eye itches, has sticky foreign body sensation, pain burning heat sensation, secretion, fear of wind, photophobia, eye sensitive to environmental stimuli
Eyeball redness, congested, keratinization and corneal epithelial wound.
21. according to the method described in any one of claim 16-20, wherein described in the liquid composition is atomized and is delivered
Each step of the atomization hydrojet of liquid composition is not related to using propellant.
22. a kind of method for treating eyes of patients illness, the method includes：
The liquid composition comprising medicinal ingredient is atomized with ultrasonic oscillating system, the atomization to form the liquid composition is sprayed
Liquid, it is drops of the about 50nm to about 1000nm that the atomization hydrojet, which includes median particle diameter,；With
To treat the upper amount for effectively mitigating eye disorders, the atomization hydrojet of liquid composition is delivered to the eye of patient in need
Portion.
23. according to the method for claim 22, wherein the liquid composition is according to any one of claim 1-9 institute
The composition stated.
24. the method according to claim 22 or 23, wherein the median particle diameter of the drop is about 100-500nm.
25. according to the method described in any one of claim 22-24, wherein the patient suffers from illness selected from the following：Eye
Eyeball is dry and astringent, is easy tired, eye itches, has sticky foreign body sensation, pain burning heat sensation, secretion, fear of wind, photophobia, eye sensitive to environmental stimuli
Eyeball redness, congested, keratinization and corneal epithelial wound.
26. according to the method described in any one of claim 22-25, wherein described in the liquid composition is atomized and is delivered
Each step of the atomization hydrojet of liquid composition is not related to using propellant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710142752.5A CN108567737B (en) | 2017-03-10 | 2017-03-10 | Liquid composition and device for using same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710142752.5A CN108567737B (en) | 2017-03-10 | 2017-03-10 | Liquid composition and device for using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108567737A true CN108567737A (en) | 2018-09-25 |
| CN108567737B CN108567737B (en) | 2020-11-27 |
Family
ID=63577494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710142752.5A Active CN108567737B (en) | 2017-03-10 | 2017-03-10 | Liquid composition and device for using same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108567737B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108815175A (en) * | 2018-04-26 | 2018-11-16 | 北京蓝丹医药科技有限公司 | A kind of spray that eye is applied outside |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101152189A (en) * | 2007-10-12 | 2008-04-02 | 成都翰朗生物科技有限公司 | Polyene phosphatidyl choline injection and method for preparing the same |
| US8673375B2 (en) * | 2008-04-10 | 2014-03-18 | Prime Interaction Holdings Limited | Herbal extract products and methods |
| CN105362220A (en) * | 2014-08-08 | 2016-03-02 | 深圳君圣泰生物技术有限公司 | Preparation, preparation method and uses thereof |
| CN105434346A (en) * | 2014-08-08 | 2016-03-30 | 深圳君圣泰生物技术有限公司 | Preparation composition and preparation method and use thereof |
| CN105435227A (en) * | 2014-08-08 | 2016-03-30 | 深圳君圣泰生物技术有限公司 | Liquid preparation composition and preparation method and use and solid preparation thereof |
| CN105435232A (en) * | 2014-08-08 | 2016-03-30 | 深圳君圣泰生物技术有限公司 | Liquid preparation composition and preparation method and use and solid preparation thereof |
-
2017
- 2017-03-10 CN CN201710142752.5A patent/CN108567737B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101152189A (en) * | 2007-10-12 | 2008-04-02 | 成都翰朗生物科技有限公司 | Polyene phosphatidyl choline injection and method for preparing the same |
| US8673375B2 (en) * | 2008-04-10 | 2014-03-18 | Prime Interaction Holdings Limited | Herbal extract products and methods |
| CN105362220A (en) * | 2014-08-08 | 2016-03-02 | 深圳君圣泰生物技术有限公司 | Preparation, preparation method and uses thereof |
| CN105434346A (en) * | 2014-08-08 | 2016-03-30 | 深圳君圣泰生物技术有限公司 | Preparation composition and preparation method and use thereof |
| CN105435227A (en) * | 2014-08-08 | 2016-03-30 | 深圳君圣泰生物技术有限公司 | Liquid preparation composition and preparation method and use and solid preparation thereof |
| CN105435232A (en) * | 2014-08-08 | 2016-03-30 | 深圳君圣泰生物技术有限公司 | Liquid preparation composition and preparation method and use and solid preparation thereof |
Non-Patent Citations (2)
| Title |
|---|
| 徐志君: "《设计性研究性物理实验》", 30 September 2012, 上海科学普及出版社 * |
| 金明: "《中医临床诊疗指南释义 眼科疾病分册》", 31 July 2015, 中国中医药出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108815175A (en) * | 2018-04-26 | 2018-11-16 | 北京蓝丹医药科技有限公司 | A kind of spray that eye is applied outside |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108567737B (en) | 2020-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3036297C (en) | Pharmaceutical compositions for use in the therapy of blepharitis | |
| CA3072768C (en) | Pharmaceutical compositions for the treatment of ophthalmic conditions | |
| DE202013012742U1 (en) | Compositions comprising mixtures of semifluorinated alkanes | |
| JP6876100B2 (en) | Liquid formulation compositions, drug delivery devices, and methods of their preparation and use | |
| WO2013171204A2 (en) | Ophthalmological vehicle system for medicaments, ophthalmological kit and use of an ophthalmological composition | |
| WO2011157428A2 (en) | In-situ lecithin microemulsion gel formulation | |
| UA112669C2 (en) | OIL DISPERSION THAT HAS A SELF-CONSERVATIVE ACTION | |
| US9801899B2 (en) | Artificial tear emulsion | |
| CN108348468A (en) | Pegylated lipids nanoparticle with bioactive lipophilic compounds | |
| CN109689161A (en) | The method of diagnosing and treating dry eye syndrome and composition for treating human eye | |
| WO2013171203A1 (en) | Fluid dispenser containing an ophthalmological composition | |
| CN107613985A (en) | The aqueous suspension liquor of nanoparticle containing glucocorticoid | |
| WO2013130242A1 (en) | Geranylgeranylacetone formulations | |
| CN108567737A (en) | Liquid composition and its use device | |
| CN100562340C (en) | A kind of micro-emulsion type artificial tear | |
| EP3412276A2 (en) | Composition for the treatment of dry eye | |
| Fassi, AR* & Naidoo | Irritation associated with tear-replacement ophthalmic drops-a pharmaceutical and subjective investigation | |
| JP6215306B2 (en) | Two-layered ophthalmic solution containing squalane | |
| CN109453151B (en) | Pharmaceutical composition for eyes, preparation method and application thereof | |
| EP3386482A1 (en) | Preservative free pharmaceutical composition for ophthalmic administration containing dexamethasone | |
| CN110279652A (en) | A kind of nano-emulsion gel eye drops that treating keratitis and preparation method | |
| CN112294762B (en) | Micelle, antifungal composition, and preparation method and application thereof | |
| Garrigue et al. | A comparative study of latanoprost-cationic emulsion (Catioprost) and latanoprost aqueous solution (Xalatan) in preclinical efficacy and safety models | |
| CN109549922B (en) | Topiramide ophthalmic composition and preparation method and application thereof | |
| CN110559261A (en) | Liposome microemulsion containing nano cross-linked hyaluronic acid and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |